Drug Maker To Pay Over $17.5M To Settle Claims It Hid Issues With Cancer Drug

BOSTON — A biopharmaceutical company and certain of its executive officers will pay more than $17.5 million to settle claims that they misrepresented poor clinical trial results for the company’s cancer...

Already a subscriber? Click here to view full article